发明名称 c-Src selected reaction monitoring assay
摘要 Objective quantitation of the c-Src protein directly in cancer patient tissue can aid in determining die aggressiveness of an individual patient's tumor as well as help make more informed decisions about choice of therapy. However, fee c-Src protein is currently analyzed directly in formalin fixed patient tissue only by immunohistoehemistry methodology which is at best subjectively semi-quantitative. This invention describes an objective quantitative assay for the c-Sre protein using mass spectrometry as the analytical methodology, Specific peptides, experimentally discovered characteristics about the peptides, and experimentally established assay conditions based on those peptide characteristics are provided for use in a mass speetronieiry-based Selected Reaction Monitoring (SRM) assay in order to measure relative- or absolute quantitative levels of c-Src directly in a protein preparation obtained from a formalin fixed cancer patient tissue sample.
申请公布号 AU2011282546(B2) 申请公布日期 2016.11.17
申请号 AU20110282546 申请日期 2011.07.29
申请人 Expression Pathology, Inc. 发明人 Krizman, David B.
分类号 G01N33/483;G01N30/72 主分类号 G01N33/483
代理机构 代理人
主权项
地址